Filing Details

Accession Number:
0001209191-16-113722
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-04-08 15:15:20
Reporting Period:
2016-04-06
Filing Date:
2016-04-08
Accepted Time:
2016-04-08 15:15:20
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
875320 Vertex Pharmaceuticals Inc / Ma VRTX Pharmaceutical Preparations (2834) 043039129
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1197023 S Joshua Boger C/O Vertex Pharmaceuticals Incorporated
50 Northern Avenue
Boston MA 02210
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-04-06 5,130 $35.35 270,414 No 4 M Direct
Common Stock Disposition 2016-04-06 900 $86.56 269,514 No 4 S Direct
Common Stock Disposition 2016-04-06 500 $88.19 269,014 No 4 S Direct
Common Stock Disposition 2016-04-06 800 $89.53 268,214 No 4 S Direct
Common Stock Disposition 2016-04-06 2,230 $90.60 265,984 No 4 S Direct
Common Stock Disposition 2016-04-06 700 $91.12 265,284 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2016-04-06 5,130 $0.00 5,130 $35.35
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
66,700 2016-07-19 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 13,286 Indirect 401(k)
Common Stock 122,700 Indirect Common Stock Held In Trust
Footnotes
  1. Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
  2. Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
  3. Open market sales reported on this line occurred at a weighted average price of $86.56 (range $86.30 to $86.81).
  4. Open market sales reported on this line occurred at a weighted average price of $88.19 (range $87.69 to $88.48).
  5. Open market sales reported on this line occurred at a weighted average price of $89.53 (range $88.95 to $89.88).
  6. Open market sales reported on this line occurred at a weighted average price of $90.60 (range $89.95 to $90.92).
  7. Open market sales reported on this line occurred at a weighted average price of $91.12 (range $90.99 to $91.41).
  8. Fully vested.